This study focuses on patients with conventional chondrosarcoma, a type of bone and joint cancer that cannot be surgically removed (unresectable) or has spread to other parts of the body (metastatic). The main treatment being tested is INBRX-109 (also known as ozekibart), which is given through an intravenous infusion. The study will compare this medication to a placebo to determine if it is effective in treating this type of cancer.

The study aims to evaluate how well INBRX-109 works in preventing cancer progression compared to placebo. Participants will receive either INBRX-109 or placebo through an intravenous infusion. Additional medications that may be given during treatment include glucose solution, acetylcysteine, dexamethasone, and diphenhydramine to manage potential side effects of the treatment.

During the study, patients will receive treatment for up to 150 days. The treatment involves regular intravenous infusions of either INBRX-109 or placebo. Doctors will monitor patients’ health status and perform regular imaging tests to check how the cancer responds to treatment. The study will track how long patients live without their cancer getting worse and measure overall survival.